TechCrunch Disrupt 2023: Day One With Shaq, Reed Jobs and Lisa Jackson

TL;DR

Biotics AI is using artificial intelligence to improve the detection of fetal abnormalities during ultrasound screenings, addressing the current issues of misdiagnosis and incomplete screenings.

Transcript

foreign thank you thank you foreign I wanna change foreign foreign foreign may I have your attention our program will begin in five minutes thank you foreign laughs [Applause] foreign [Applause] thank you may I have your attention our program is about to begin please silence on mobile devices um [Laughter] thank you [Music Read More

Key Insights

• 🛄 Biotics AI aims to address the challenges of misdiagnosis and incomplete ultrasound screenings for fetal abnormalities.
• 🤩 The software solution offers real-time feedback to ultrasound operators, ensuring the comprehensive capture of key structures during screenings.

Questions & Answers

Q: How does Biotics AI address the issue of incomplete ultrasound screenings?

Biotics AI uses artificial intelligence to analyze ultrasound images and provide real-time feedback to ultrasound operators. This helps ensure that all key structures and anatomical views are captured, reducing the likelihood of incomplete screenings.

Q: What is the business model for Biotics AI?

Biotics AI sells its software solution to hospitals, offering a hybrid pricing model with a baseline subscription cost and additional charges based on the volume of API calls made to their algorithms. This model allows hospitals to benefit from time savings and increased efficiency in reporting and documentation.

Q: How does Biotics AI integrate with ultrasound machines?

Biotics AI is vendor-agnostic and can integrate with any ultrasound machine through a standard API. It can be accessed via an iPad or other devices, providing seamless integration into the ultrasound workflow.

Summary

This video features three different startups presenting their innovative ideas in different industries. The first startup, In Diagnostic, showcases a portable blood testing device that eliminates the need for traditional blood analyzers. The second startup, Narval, presents a synthetic antibody mimetic protein platform that aims to develop antibody drugs for various diseases. The third startup, Flint, introduces paper batteries as a sustainable and cost-effective alternative to traditional batteries. Each startup provides detailed information about their product, its advantages, and its potential applications.

Questions & Answers

Q: What does In Diagnostic's portable blood testing device do?

In Diagnostic's device simplifies blood testing by eliminating the need for traditional blood analyzers. It integrates a centrifuge, spectrophotometer, and a USB connection to a smartphone. Users can obtain test results on their phone in real-time.

Q: How does In Diagnostic plan to expand its menu of blood tests?

In Diagnostic plans to expand its menu of blood tests by changing the reagents and filters in the device. The company aims to develop tests for various indications, such as liver enzymes, creatine kinase, and more.

Q: How does In Diagnostic ensure accuracy and precision in its blood tests?

In Diagnostic's device uses small cuvettes to measure blood samples with better than 3% precision on the path length. The device also includes a microchip that digitizes the opacity of the sample and runs the data through a USB-C dongle.

Q: How does Narval's synthetic antibody mimetic protein platform differ from traditional monoclonal antibodies?

Narval's platform utilizes a synthetic antibody mimetic protein platform that combines CDR3 regions from single domain shark antibodies with a synthetic protein scaffold from a sea snail. This combination allows for smaller, cross-tissue barrier penetration, limited immune reactions, and heat resistance.

Q: What diseases or indications is Narval's synthetic antibody mimetic protein platform targeting?

Narval's platform aims to target diseases such as diabetic retinopathy, respiratory diseases, and COVID-19. They have shown promising results in preclinical testing and plan to conduct clinical trials in the near future.

Q: How does Flint's paper battery differ from traditional lithium batteries?

Flint's paper batteries utilize hydrogel-reinforced cellulose paper, zinc, and manganese as the battery materials. They are fully compostable, lightweight, flexible, and cost-effective compared to traditional lithium batteries. They can be shaped into various forms and sizes, making them adaptable to different products.

Q: What are the advantages of using Flint's paper batteries?

Flint's paper batteries offer a sustainable and cost-effective solution for battery technology. They are fully compostable, reducing environmental impact and making recycling easier. The cost of manufacturing the paper batteries is ten times cheaper than traditional lithium batteries. The batteries also offer comparable or improved performance in terms of capacity, volume, and weight.

Q: What are the potential applications of Flint's paper batteries?

Flint's paper batteries can be used in a wide range of applications, including energy storage systems, consumer tech, wearables, remote sensors, and even explosives' remote trigger systems. The company is already collaborating with companies in the energy storage and pyrotechnic industries to implement their paper batteries.

Takeaways

The three startups featured in the video present innovative solutions in their respective industries. In Diagnostic's portable blood testing device aims to simplify and make blood testing more accessible. Narval's synthetic antibody mimetic protein platform has the potential to revolutionize antibody drug development for various diseases. Flint's paper batteries offer a sustainable and cost-effective alternative to traditional batteries, opening up possibilities for greener energy storage and consumer tech. These startups demonstrate the power of innovation in driving positive change and addressing pressing challenges in different sectors.

Summary & Key Takeaways

• Biotics AI is a software solution that enhances the quality of ultrasound screenings for fetal abnormalities.

• The platform ensures comprehensive and accurate screenings by providing real-time feedback to ultrasound operators and automating reporting and documentation.

• With the ability to detect abnormalities early and increase the completeness of screenings, Biotics AI aims to improve maternal outcomes and reduce preventable complications.